Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 11/20 | 0.49 |
| ▸ | BCHE | P06276 | 6/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15323603 | 0.89 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTACHEBCHE | |
| SCHEMBL15323027 | 0.84 | BCHE (0.43) | ALDH1A1KDM4EMAPTACHEBCHE | |
| SCHEMBL15323026 | 0.84 | BCHE (0.43) | ALDH1A1KDM4EMAPTACHEBCHE | |
| SCHEMBL16589523 | 0.84 | BCHE (0.47) | ALDH1A1KDM4EMAPTACHEBCHE | |
| SCHEMBL15324505 | 0.83 | MAPT (0.48) | ALDH1A1KDM4EMAPTACHEBCHE | |
| SCHEMBL15324508 | 0.83 | MAPT (0.48) | ALDH1A1KDM4EMAPTACHEBCHE | |
| SCHEMBL15325743 | 0.81 | BCHE (0.53) | ALDH1A1KDM4EACHEBCHECYP2C19 | |
| SCHEMBL15322761 | 0.80 | BCHE (0.40) | ALDH1A1KDM4EMAPTACHEBCHE | |
| SCHEMBL15322764 | 0.80 | BCHE (0.40) | ALDH1A1KDM4EMAPTACHEBCHE | |
| SCHEMBL16589524 | 0.80 | MAPT (0.54) | ALDH1A1KDM4EMAPTACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499484-B2 | Indole, indoline derivatives, compositions comprising them and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2016-11-22 | — | — | US | disclosed |
| US-20150087617-A1 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2015-03-26 | — | — | US | disclosed |
| WO-2013150529-A2 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2013-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087617-A1 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | IDO1, INMT, IDO2 | ALDH1A1 840/4885KDM4E 973/4885MAPT 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.